Healio

NODE-301: Etripamil may benefit patients with paroxysmal supraventricular tachycardia

As Healio previously reported, in the main results of NODE-301, etripamil (Millstone Pharmaceuticals), an L-type calcium channel blocker administered via nasal spray, missed the primary endpoint of ...
MedPage Today

'Groundbreaking' Results With Nasal Spray for Home Tachycardia Conversion

CHICAGO -- The investigational L-type calcium channel blocker etripamil, formulated as a self-administered nasal spray, shortened spontaneous paroxysmal supraventricular tachycardia episodes among ...
Business Wire

2019 Paroxysmal Supraventricular Tachycardia Pipeline Insights Report - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Paroxysmal Supraventricular Tachycardia- Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering. A detailed picture of the Paroxysmal ...
Medscape

More Good News for Self-Administered Nasal Spray in PSVT

The investigational intranasal L-type calcium channel blocker etripamil continues to be well tolerated and effective for self-treating recurrent episodes of paroxysmal supraventricular tachycardia ...
Healio

Self-administered nasal spray ‘rapidly’ treats paroxysmal supraventricular tachycardia

Please provide your email address to receive an email when new articles are posted on . CHICAGO — A fast-acting nasal spray safely and effectively converted episodes of paroxysmal supraventricular ...

Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adu…

CARDAMYST is now conveniently available to patients through retail pharmaciesNational sales force hired with promotional ...
PR Newswire

Paroxysmal Supraventricular Tachycardia Market to Show Immense Growth During the Study Period (2020-2034) | DelveInsight

According to DelveInsight's estimates, the paroxysmal supraventricular tachycardia market in the 7MM is expected to show positive growth, during the forecast period (2024–2034), mainly attributed to ...
Labroots

Self-Treating Tachycardia: One Step Closer to an In-Pocket Option

A sudden, rapid heart rate will send many to the emergency room. Every year, more than 140,000 emergency room visits are related to a specific type of increased heart rate called paroxysmal ...
Medscape

Self-Administered Etripamil Cuts Emergency Department Visits for Paroxysma Supraventricular Tachycardia

Self-administered intranasal etripamil was nearly twice as likely as placebo to terminate a paroxysmal supraventricular tachycardia (PSVT) episode within 30 minutes and reduced emergency department ...
WGHP

Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)

As such, Milestone will leverage the approved PSVT indication and the PSVT program data, along with a single pivotal Phase 3 study in patients with AFib-RVR. About Paroxysmal Supraventricular ...
Nasdaq

Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)

MONTREAL and CHARLOTTE, N.C., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that the U.S. Food and Drug Administration (FDA) approved its first ...